US · Healthcare · Diagnostics & Research
EPS came in at 1.44 against a street estimate of 1.36 — a beat of 5.9%.
Analysts rate Illumina Inc a hold (10 buy, 7 hold, 4 sell out of 21) with an average price target of $261.60.
CONFIDENT Illumina delivered a strong Q3, led by clinical sequencing and NovaSeq X placements, and raised 2026 revenue, margin, and EPS guidance while signaling confidence in 2027 growth. Q3 FY26 Rest of World organic revenue grew 5%; management said clinical demand remains strong and research activity is stabilizing. Analysts focused on clinical growth durability, NovaSeq X demand, 2027 targets, margins, AI monetization, and pricing. Management emphasized sustained clinical demand, expanding installed capacity, and long-term multi-omics and AI opportunities. 2026-10-29…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 12.71% |
| Capital World Investors | 10.22% |
| Vanguard Portfolio Management, LLC | 4.39% |
| Vanguard Capital Management, LLC | 4.36% |
| State Street Corp | 4.31% |
| WCM Investment Management | 4.11% |
| FMR Inc | 3.00% |
| AQR Capital Management LLC | 2.35% |
| Document | Date |
|---|---|
| Quarterly report · Q3 FY2027 HEADLINE NUMBERS • Q3 2026 revenue was $1,129 million, up from $1,084 million in Q3 2025. • Q3 2026 net income was $220 million, compared with $150 | 2026-10-30 |
| Results announced · Q3 FY2027 HEADLINE NUMBERS • Q3 2026 revenue was $1.13 billion, up 4.2% from Q3 2025. Excluding tariff refunds and adjusting for currency, acquisitions, and Gr | 2026-10-29 |
| Material agreement · Q3 FY2027 HEADLINE NUMBERS • Illumina established an unsecured commercial paper program with borrowing capacity of up to $1.0 billion. • As of October 13, 202 | 2026-10-13 |
| Company announcement · Q3 FY2027 ILLUMINA, INC. - 8-K SUMMARY HEADLINE NUMBERS • Debt Offering: Illumina completed a public offering of $300 million in notes on August 17, 2026 • I | 2026-08-17 |
| Material agreement · Q3 FY2027 ILLUMINA, INC. – FORM 8-K SUMMARY Report Date: August 13, 2026 --- HEADLINE NUMBERS • New credit facility size: $1,000 million senior unsecured rev | 2026-08-13 |
| Company announcement · Q3 FY2027 ILLUMINA, INC. - 8-K SUMMARY HEADLINE NUMBERS • Illumina is issuing $300,000,000 in new debt notes with a 4.950% interest rate, due 2029 • Expected | 2026-08-12 |
| Company announcement · Q3 FY2027 ILLUMINA, INC. - DOCUMENT SUMMARY HEADLINE NUMBERS • Settlement effective date: August 21, 2025 • Court hearing date: November 2, 2026, at 1:30 p.m. | 2026-08-07 |
| Quarterly report · Q2 FY2027 ILLUMINA, INC. - Q2 2026 FORM 10-Q SUMMARY HEADLINE NUMBERS • Revenue (Q2 2026): $1,159 million (+9.4% vs Q2 2025: $1,059 million) - Product reven | 2026-07-31 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Split | 1028 : 1000 effective Jun 25, 2024 | 2024-06-25 |
| Announcement | Date |
|---|---|
| Board authorizes new $1.5 billion share repurchase program Illumina issued an 8-K filing on April 30, 2026, announcing Q1 2026 financial results for the quarter ended March 29, 2026. The actual earnings details are not included in this 8-K document | 2026-04-30 |
| Completion of transaction announced; integration of acquired business underway On January 30, 2026, Illumina, Inc. completed its acquisition of Standard BioTools Inc., a transaction that was originally announced on June 22, 2025. The specific purchase price and financi | 2026-01-30 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Illumina Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.